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Special issue: Molecular basis of the NCLsThe neuronal ceroid lipofuscinoses (NCLs), often known as Batten
disease, are a group of rare and devastating neurodegenerative dis-
orders. They commonly affect children but can strike at any age,
from before birth up to late in life. They are genetic diseases, usu-
ally inherited in an autosomal recessive manner, and at present are
incurable.
This special issue follows the latest international meeting on
the NCLs—the 13th international congress, NCL2012 (http://www.
ncl2012.org)—which was held in March 2012 in London, United
Kingdom, and attended by a total of >150 clinical, scientiﬁc and pro-
fessional experts from around the world. There were 50 talks and
64 posters, and 2 outreach workshops for professionals. Additional
satellite meetings included those of the DEM-CHILD Consortium,
funded by the European Union, which ranged from meetings of those
collaborating on work packages, to training for families and profes-
sionals, and a gathering of all PhD students. This European Consortium
has since expanded to include international clinical collaboration cen-
tering on the natural history of the NCLs.
In addition to these scientiﬁc and clinical activities, there was a
parallel Family Conference hosted by the UK Batten Disease Family
Association that was attended by nearly 100 families with some ses-
sions held jointly with the scientiﬁc conference, including an innova-
tive and popular shared interactive ‘market place’ event (with 12
‘stalls’) that shared the wide expertise of all of those present. This
integration of science, clinical, professional and lay perspectives with-
out diluting what is essentially a scientiﬁc meeting exempliﬁes a new
format of meeting. This can be further built upon in future scientiﬁc
congresses in this ﬁeld, for other rare diseases, and adapted for use
in other ﬁelds.
We commissioned a series of reviews from attending experts, delib-
erately requesting shared co-authorship across different institutions
to reﬂect the excellent cooperative international expertise that exists,
a particular feature perhaps of research into a rare disease. The aim of
these reviews is to provide articles that summarise the current status
of the NCL ﬁeld.
The ﬁrst review (Haltia and Goebel) deliberately looks to the past
since the NCLs were ﬁrst proposed as a distinct clinical diagnosis in
the late 1960s, but are now increasingly deﬁned on the basis of
their genetics. This ensures that relevant knowledge and experience
built up over these years is not forgotten, but can be integrated
with new developments, such as recent changes in disease nomencla-
ture, as well as highlighting key historical landmarks. The genetic
basis of the NCLs including the number of genes and mutations, and
correlations with phenotype since some mutations cause disease of
a very different clinical course, are discussed by Warrier et al., as0925-4439/$ – see front matter © 2013 Published by Elsevier B.V.
http://dx.doi.org/10.1016/j.bbadis.2013.05.025well as providing links to the updated web-based NCL Mutation
and Family Databases.
Bioinformatic approaches have become more sophisticated and
used to advance research particularly in the areas of establishing the
genetic basis of disease in individual families and in predicting the
molecular basis of NCL disease. These new and recent approaches in
the NCL ﬁeld are summarised by Kmoch et al.
A review on the clinical perspectives of the NCLs summarises fea-
tures of the different NCLs, such as range of ages at onset and presenting
symptoms, and characteristics of progression (including involvement of
organs outside the nervous system), together with a recently adopted
new nomenclature, and a guide to diagnosis (Schulz et al.). This is com-
plemented by a review on the pathology of NCL, long used in diagnosis
and still important in establishingNCL especiallywhen commongenetic
or biochemical causes have been quickly excluded (Anderson et al.).
Those affectedwithNCL as childrenmay live into adulthood and so at-
tend school for many years. Elmerskog and colleagues review NCL from
an educational perspective, a view that many families ﬁnd extremely
helpful as they interact with professionals who support them.
An established and productive focus of disease research is the
derivation or recognition and use of experimental model organisms,
from unicellular models up to large animal models (Bond et al.) and
the use of mammalian cell systems and models to understand the
molecular basis of the disease itself, by studying the expression, func-
tion and regulation of NCL proteins and their impact on lysosomal integ-
rity (Kollman et al.). From these studies comes a further understanding
of the disease mechanisms (Palmer et al.), and this knowledge forms
the basis for current and future therapeutic development. Hawkins-
Salsbury et al. highlight recent advances in studying experimental thera-
pies for CLN1 disease, aswell as touching on other forms of NCL. Progress
in reaching new treatments or therapy is always of particular interest to
families, whether curative or one that halts progression or impacts upon
part of the disease.
The NCLs continue to surprise and intrigue, more than one hundred
years after their ﬁrst description and twenty years after the ﬁrst genes
were identiﬁed. New or improved approaches to research, clinical and
professional care continue despite the ﬁnancial climate.
NCL non-proﬁt Organisations initiated by parents around the world
are also playing an increasingly important role in supporting families as
well as research both locally and collaboratively. This is exempliﬁed by
their providing additional sources of funding for research into Batten
disease in recent years, which has been summarised by Stehr and
Forkel. Many of these organisations were well represented at the meet-
ing, and indeed shared their perspectives with the attending scientists,
clinicians and other professionals.
1794 PrefacThese articles were commissioned to be helpful to those new to
the ﬁeld, as well as providing useful summaries and perspectives to
those long familiar with the NCLs. Useful tables and summaries can
also be found on various internet sites, including the NCL Resource
that hosts the NCL Mutation database (www.ucl.ac.uk/ncl). Social
media was active prior to, during and after the conference and can
still be accessed (Facebook: NCL2012; Twitter @ncl2012, #ncl2012
and #battendisease). Progress in the NCL ﬁeld will continue to be
reported at biennial international meetings, with the next being the
14th International Conference on NCL and Patient Organisation Meet-
ing planned for Cordoba in Argentina, 22–26 October, 2014.Sara Mole PhD, Reader in Molecular Cell Biology, MRC
Laboratory for Molecular Cell Biology and UCL Institute of
Child Health, and Dept Genetics, Evolution & Environment,
University College London.
Dr Mole is a Reader in Molecular Cell Biology at University
College London and her research has focused on Batten dis-
ease for 20 years. Prior to this she read Natural Sciences at
the University of Cambridge, completing research work in
the ﬁeld of cancer research for her PhD and two postdoctoral
positions. An appointment as Lecturer in 1992 allowed her
to apply the developing ﬁeld of molecular genetics to the
ﬁrst gene identiﬁcation for Batten disease. This continues
for small groups of families still without a genetic diagnosis,
using the latest DNA technologies on a collection of samples
from over 600 families. DrMole's lab has a special interest in NCL genes that encodemem-
brane proteins, and has specialised in using yeast as a simple cellular model to understand
the biology of CLN3 disease and to identify new targets for therapeutic development. They
are also developing gene therapy that targets the visual failure of Batten disease, using
mouse models, with the ultimate aim of a therapy that will reach and work in the brain.
Dr Mole is the senior editor of a specialised book on Batten disease, published in 2011 by
OxfordUniversity Press. She set up aweb site in 1998 (NCL Resource—a gateway for Batten
disease) that includes themutation database as well as diagnostic advice for clinicians and
information for newly diagnosed families. She is scientiﬁc advisor to theUK BattenDisease
Family Association. Dr Mole co-organised the last international meeting on Batten disease
(in 2012, Royal Holloway College, London) that led to the award by the UCL Provost of
Public Engager of the Year (senior staff).Dr. Ruth Williams is a Consultant Paediatric Neurologist at
Guy's and St Thomas' NHS Foundation Trust in London. She
qualiﬁed in Medicine from the University of Nottingham in
1985 and went on to train in Paediatrics and Paediatric Neu-
rology in Birmingham, Bath and London. She now specialises
in the diagnosis and management of epilepsy in children
and leads the Dietary Epilepsy Service at Evelina Children's
Hospital. Ruth ﬁrst encountered Batten disease as a junior
doctor. She went on to work alongside Dr Sara Mole and
others at University College London on the initial genetic
studies of late infantile Batten disease in the early 1990s. She
now helps care for a large number of children and families af-
fected by all types of NCL in the UK. She was Medical Advisor
to the BDFA from its beginnings until 2012. She co-hosted the
NCL-2012 Congress in London and co-edited the second edition of ‘The Neuronal Ceroid
Lipofuscinoses (Batten Disease)’, a comprehensive NCL textbook.Jonathan Cooper PhD. Professor of Experimental Neuro-
pathology, Pediatric Storage Disorders Laboratory (PSDL),
Institute of Psychiatry, King's College London.
Prof Cooper founded the PSDL when hewas appointed at the
Institute of Psychiatry, King’s College London in 2000. Prior to
this he trained in Anatomy and Cell Biology (BSc, Shefﬁeld),
and Neuroanatomy (PhD, Bristol), and spent time as a post-
doctoral researcher at the University of Cambridge, the Max-
Planck-Institute for Psychiatry (Martinsried, Germany), and
in California at the University of California, San Francisco
and StanfordUniversity.Duringmuch of this timehe focussed
on issues surroundingwhy particular neuron populations are
eaffected in neurodegenerative diseases, concentrating upon
the cholinergic basal forebrain and the inﬂuence of
neurotrophins upon them. He ﬁrst encountered the NCLs while in the USA, and when he
started a lab chose to focus upon these childhood disorders.
The PSDL has described many of the important neuropathological features of the NCLs,
deﬁning vulnerable neuron populations and the relationship of storagematerial accumula-
tion, glial activation and synaptic pathology to this neuron loss. The lab also continues to be
involved in a range of pre-clinical studies assessing the efﬁcacy of a range of experimental
therapies, and collaborates widely with colleagues around theworld. He also works closely
with the affected families, and played amajor role in co-organising NCL2012, the 13th
International Congress on NCL research that was held at the Royal Holloway College
in March 2012. For the ﬁrst time this congress featured a parallel meeting for the
Patient Organisations, with shared sessions and novel initiatives to make the science
conference accessible to all.
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